Primary radiotherapy with endobronchial high-dose-rate brachytherapy boost for inoperable lung cancer: long-term results
BackgroundTo retrospectively evaluate the outcome of patients with inoperable non-small-cell lung cancer treated with primary external beam radiotherapy combined with high-dose-rate endobronchial brachytherapy boost.Patients and methodsBetween 1988 and 2005, 35 patients with non-small-cell lung canc...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2013
|
| In: |
Trends in plant science
Year: 2013, Volume: 99, Issue: 2, Pages: 183-190 |
| ISSN: | 1878-4372 |
| DOI: | 10.1177/030089161309900211 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1177/030089161309900211 Verlag, lizenzpflichtig, Volltext: https://journals.sagepub.com/doi/10.1177/030089161309900211 
|
| Author Notes: | Nathalie Rochet, Henrik Hauswald, Eva Maria Stoiber, Frank W Hensley, Heinrich D Becker, Juergen Debus, and Katja Lindel |
| Summary: | BackgroundTo retrospectively evaluate the outcome of patients with inoperable non-small-cell lung cancer treated with primary external beam radiotherapy combined with high-dose-rate endobronchial brachytherapy boost.Patients and methodsBetween 1988 and 2005, 35 patients with non-small-cell lung cancer (stage I-III) ineligible for surgical resection and/or chemotherapy, were primarily treated with external beam radiotherapy with a median total dose of 50 Gy (range, 46?60). A median of 3 fractions high-dose-rate endobronchial brachytherapy was applied as a boost after external beam radiotherapy, the median total dose was 15 Gy (range, 8?20). High-dose-rate endobronchial brachytherapy was carried out with iridium-192 sources (370 GBq) and prescribed to 1 cm distance from the source axis.ResultsWith a median follow-up of 26 months from the first fraction of high-dose-rate endobronchial brachytherapy, the 1-, 2- and 5-year overall (local progression-free) survival rates were 76% (76%), 61% (57%) and 28% (42%), respectively. Complete or partial remission rates 6 to 8 weeks after treatment were 57% and 17%, respectively. Significant prognostic favorable factors were a complete remission 6?8 weeks after treatment and a negative nodal status. In patients without mediastinal node involvement, a long-term local control could be achieved with 56% 5-year local progression-free survival. Common Toxicity Criteria grade 3 toxicities were hemoptysis (n = 2) and necrosis (n = 1). One fatal hemoptysis occurred in combination with a local tumor recurrence.ConclusionsThe combination of external beam radiotherapy with high-dose-rate endobronchial brachytherapy boost is an effective primary treatment with acceptable toxicity in patients with non-small-cell lung cancer ineligible for surgical resection and/or chemotherapy. |
|---|---|
| Item Description: | Article first published online: January 29, 2018 Gesehen am 17.01.2022 |
| Physical Description: | Online Resource |
| ISSN: | 1878-4372 |
| DOI: | 10.1177/030089161309900211 |